Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Breast cancer
H&E-Based Gene-Expression Signature Stratifies pCR 8% vs 59% in ISPY2 Neoadjuvant Breast-Cancer Study
A transformer model capable of inferring 38 gene-expression signatures directly from biopsy H&E slides was applied to 579 HER2-negative patients in the I-SPY2 trial (chemotherapy ± immunotherapy). An…
- Trial result
Breast cancer
Anti-CD73 Oleclumab Fails but ctDNA Wins in First-Line mTNBC
In the randomized Phase I/II SYNERGY trial (NCT03616886), 133 untreated patients with locally advanced or metastatic triple-negative breast cancer (TNBC) received weekly carboplatin (a platinum-based chemotherapy)…
NCT03616886 - Trial result
Breast cancer
High-Grade Neutropenia Marks Palbociclib Benefit in Early HR-Positive Breast Cancer
In PALLAS (N = 5,736 stage II–III HR+/HER2- cases), adding the CDK4/6 inhibitor palbociclib to adjuvant endocrine therapy (ET) failed overall, but an exploratory look at the 2,840 palbo-treated patients showed that…
- Trial result
Prostate cancer
Abiraterone Without Ongoing GnRH Holds Testosterone Down and Delivers 27-Month PFS in Metastatic Prostate Cancer
Abiraterone, a CYP17 inhibitor that is approved for prostate cancer, + prednisone was given to 31 men with metastatic prostate cancer after stopping their GnRH analogue in this single-arm Phase II study…
NCT03565835 - Trial result
Prostate cancer
HSV- Thymidine-Kinase Gene Therapy CAN-2409 + Valacyclovir Cuts Recurrence 30% with EBRT in Localized Prostate Cancer
CAN-2409 is a replication-defective adenovirus delivering HSV-thymidine-kinase. When combined with oral valacyclovir, CAN-2409 triggers immunogenic cell death. In the double-blind Phase 3 trial NCT01436968, 745…
NCT01436968 - Trial result
Prostate cancer
High PSMA PET Tumor Volume Halves 5-Year PFS in ENZAMET mHSPC Sub-Cohort
In an ENZAMET substudy, 100 patients received testosterone suppression with either enzalutamide or a control non-steroidal antiandrogen then underwent a semi-automated PSMA total tumor volume (TTV) quantified on…
- Trial result
Prostate cancer
Methylation-Based Tumor Fraction (ctDNA) Beats PSA for Predicting Rucaparib Outcomes in BRCA deficient mCRPC
In TRITON2 (NCT02952534), a Phase 2 study of rucaparib (an approved PARP inhibitor) in BRCA mutation deficient (germline and/or somatic) metastatic castration-resistant prostate cancer, a lower baseline plasma tumor…
NCT02952534 - Trial result
Prostate cancer
Rucaparib Boosts PFS Across Germline and Somatic BRCA-Mut mCRPC in TRITON3
Rucaparib, an oral PARP inhibitor, was compared with physician’s-choice docetaxel or abiraterone/enzalutamide in the Phase 3 TRITON3 trial (NCT02975934) in the ~13% of patients with BRCA deficient metastatic…
NCT02975934 - Trial result
Prostate cancer
Short-Course ADT + Apalutamide ± Abiraterone with SBRT Yields ≥85% 18-mo PFS in PSMA-PET Oligometastatic Prostate Cancer
In the randomized phase II Metacure B2 study (NCT03436654) and its expansion (n = 36), men with PSMA-PET-detected metachronous oligometastatic, hormone-sensitive prostate cancer received stereotactic body…
NCT03436654 - Trial result
Multiple solid tumors
Entrectinib Nets 69% ORR in Children with ROS1-Fusion Solid & CNS Tumors
Entrectinib, an oral TRK/ROS1 inhibitor, was pooled across the phase 1–2 STARTRK-NG (NCT02650401), TAPISTRY (NCT04589845), and STARTRK-2 (NCT02568267) trials. Across 26 ROS1-fusion patients (<18 y) there was a 69%…
NCT02650401 - Trial result
Multiple solid tumors
Pembrolizumab Clears Tumors in 58% of MSI-H Cancers, 47% Alive at 10 Years
PD-1 inhibitors, like pembrolizumab, showed strong efficacy in dMMR/MSI-H cancers. KEYNOTE-016 (NCT01876511), a multicenter phase 2 trial, gave pembrolizumab 2 mg/kg Q2W to 88 adults with heavily pre-treated…
NCT01876511 - Trial result
Multiple solid tumors
GFH375 KRAS-G12D Inhibitor Delivers 38% ORR — 52% in Pancreatic Cancer
GFH375 is an oral inhibitor that locks mutant KRAS G12D in both its GDP- and GTP-bound states. In a first-in-human Phase I/II study in China (NCT06500676), 32 heavily pre-treated patients with KRAS G12D-mutant solid…
NCT06500676 - Trial result
Multiple solid tumors
ctDNA Drop ≥50% by Cycle 3 Flags Long-Term Benefit from Atezolizumab Across Solid Tumors
Cell-free DNA (cfDNA) refers to fragments of DNA released into the bloodstream from dying cells, including circulating tumor DNA (ctDNA) from cancer cells. In the MyPathway pan-tumor cohort (phase II, n = 153;…
NCT02091141 - Trial result
Multiple solid tumors
Pralsetinib RET Inhibitor Shrinks Diverse Tumors (46% ORR, 11-mo DoR)
Pralsetinib is a tyrosine kinase inhibitor designed to target cancer-driving RET fusions and mutations. In the Phase 2 ARROW basket trial (n = 29; 11 histologies, NCT03037385), adults with pre-treated, RET…
NCT03037385 - Trial result
Non-small cell lung cancer
Oral HER2-selective TKI Zongertinib Logs 71% ORR and 12-mo PFS in Pretreated HER2-Mutant NSCLC
Zongertinib (BI 1810631) is an irreversible HER2 tyrosine-kinase inhibitor that spares EGFR. In the phase Ia/Ib Beamion LUNG-1 study (AACR CT050; NCT04886804), 75 previously treated advanced NSCLC patients with HER2…
NCT04886804 - Trial result
Non-small cell lung cancer
Zoldonrasib (RMC-9805) Hits 61% ORR in KRAS-G12D–Mutant NSCLC Dose-Expansion presented at AACR
Zoldonrasib is an oral, RAS(ON) G12D-selective “tri-complex” inhibitor that locks mutant KRAS to cyclophilin A. In the Phase 1 RMC-9805-001 study (NCT06040541), 18 heavily pre-treated NSCLC patients with KRAS G12D…
NCT06040541 - Trial result
Non-small cell lung cancer
MK-1084 (KRAS G12C inhibitor) + pembrolizumab drives 74% ORR and 25-month PFS in first-line metastatic NSCLC
MK-1084 is an oral, next-gen covalent inhibitor that locks KRAS G12C in its inactive GDP form. In the phase 1 KANDLELIT-001 trial (NCT05067283), 21 previously treated NSCLC showed a 38% ORR and mPFS of 8 months with…
NCT05067283 - Trial result
Non-small cell lung cancer
Atezolizumab (PD-L1 mAb) Halves 5-Year Recurrence & Mortality Risk in PD-L1-High Resected NSCLC
Atezolizumab is a monoclonal antibody that targets PD-L1. In the open-label phase III IMpower010 trial (NCT02486718), 1,005 patients with completely resected stage IB–IIIA NSCLC were randomized to receive…
NCT02486718 - Trial result
Non-small cell lung cancer
Larotrectinib Delivers 69% ORR and 22-mo PFS in TRK-Fusion Lung Cancer
Larotrectinib, a highly selective CNS-penetrant TRK inhibitor, was evaluated in two Phase 1/2 trials (NCT02122913, NCT02576431) involving 32 patients with advanced TRK-fusion lung cancer—59% had ≥2 prior therapies…
NCT02122913 - Trial result
Head and neck cancer
SIRPα blocker BI 765063 + PD-1 (ezabenlimab) + cetuximab drives 47% ORR in 2L SIRPα-V1 HNSCC
In an open-label Phase Ib trial (NCT05249426), 17 eligible patients with recurrent/metastatic HNSCC after one prior systemic therapy—all homozygous for the SIRPα V1 allele—received BI 765063, a signal regulatory…
NCT05249426 - Trial result
Head and neck cancer
Pembrolizumab (PD-1) boosts peri-operative EFS in resectable head-and-neck SCC by ~21 mo
In the Phase 3 KEYNOTE-689 study (NCT03765918), 714 adults with stage III–IVA, resectable HNSCC were randomised to two neoadjuvant cycles, three concurrent cycles (during PORT), and 12 adjuvant cycles of…
NCT03765918 - Trial result
Head and neck cancer
T-DM1 Hits 88% Response in HER2-Amplified Salivary Gland Cancers in Basket Trial
Ado-trastuzumab emtansine (T-DM1), an HER2-targeted antibody–drug conjugate approved for breast cancer, was tested in a single-arm Phase 2 basket study (NCT02675829) enrolling 88 patients with HER2-amplified NSCLC,…
NCT02675829 - Trial result
Head and neck cancer
ROR2-ADC Ozuriftamab Vedotin Posts 36% ORR in PD-1-Refractory Head-and-Neck Cancer
Ozuriftamab vedotin is a conditionally binding antibody–drug conjugate that releases MMAE only in the low-pH tumor microenvironment to target ROR2. In this open-label Phase 2 trial (NCT03504488), 31 patients with…
NCT03504488 - Trial result
Melanoma
Nivolumab + Ipilimumab First Doubles 5-Year OS vs Dabrafenib/Trametinib in BRAFV600-Mutant Melanoma
In the Phase III DREAMseq trial (NCT02224781), 267 untreated patients with BRAF V600-mutant metastatic melanoma were randomized to receive either nivolumab (a PD-1–directed monoclonal antibody) plus ipilimumab (a…
NCT02224781 - Trial result
Melanoma
One-Time TIL Therapy Lifileucel Delivers 31% ORR with 3-Year Median Response and 20% 5-Year Survival in Heavily Pretreated Melanoma
Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) product administered following non-myeloablative lymphodepletion and high-dose interleukin-2 (IL-2). In the Phase 2 C-144-01 trial (*n* = 153; median of…
- Trial result
Ovarian cancer
CA125-Targeted Oregovomab Added to Carboplatin/Paclitaxel Hits 10-Year OS 121 mo vs 65 mo in Optimally Debulked Stage III/IV Ovarian Cancer
Oregovomab is a monoclonal antibody that engages host immunity against the protein CA125, which is expressed in ovarian cancer cells. In the randomized QPT-ORE-002 Phase II trial (NCT01616303), 97 women with…
NCT01616303 - Trial result
Ovarian cancer
IL-12 Gene Therapy IMNN-001 Adds 13-Month OS to Front-Line Chemo in Advanced Ovarian Cancer
IMNN-001 works by stimulating local production of IL-12, which activates immune cells to attack the cancer. In the randomized phase I/II OVATION-2 trial (NCT03393884), 112 women with stage III/IV epithelial ovarian…
NCT03393884 - Trial result
Sarcoma and GIST
Dendritic-Cell Vaccine Shows Durable Control in 20% of Metastatic Sarcoma, Tied to T-Cell–Rich Tumor Microenvironment
In a Phase I trial (NCT01803152), 19 patients with advanced or metastatic sarcoma received an autologous dendritic-cell vaccine after prior therapies; median PFS was 9.5 months, with 4 (21%) long-term responders (>2…
NCT01803152 - Trial result
Sarcoma and GIST
Anti-PD-L1 Avelumab + VEGFR TKI Axitinib Delivers 40% ORR in MMR-Proficient Endometrial Cancer
In a two-stage Phase 2 study (NCT02912572) anti-PD-L1 Avelumab plus the VEGFR1-3 tyrosine kinase inhibitor, axitinib, was evaluated in 35 patients with recurrent or persistent mismatch-repair-proficient endometrial…
NCT02912572 - Trial result
Small cell lung cancer
Trispecific DLL3 T-Cell Engager ZG006 Delivers 67% ORR in Post-PD-1 Small-Cell Lung Cancer
ZG006 is a bispecific antibody that bridges CD3+ T cells to two DLL3 epitopes. In a Phase 2 dose-expansion study (NCT06283719) involving 40 heavily pretreated small-cell lung cancer (SCLC) patients (≥2 prior lines of…
NCT06283719
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.